Backs FY25 revenue view at least $385.9B, consensus $388.85B. Backs FY25 free cash flow view $6.5B. Backs FY25 capital expenditures view $2.8B-$3B. The company said, “Based on year-to-date results through February, the Company currently expects financial results will meet or exceed its previously issued guidance for full year 2025. Our financial closing procedures for the first quarter of 2025 are not yet complete and, as a result, expected results for the full year may change due to such financial closing procedures, final adjustments, management’s review of results, and other developments that may arise between now and the time our financial results for the first quarter of 2025 are finalized.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- CVS Health CFO Tom Cowhey to transition to advisor role, Brian Newman to succeed
- Positive Outlook for CVS Health Amid Medicare Advantage Rate Increase and Margin Expansion Potential
- Five Best Stocks to Buy in Today’s Fearful Market, According to Analysts
- Trump Weekly: U.S. announces new tariffs, China responds with their own
- Amneal Pharmaceuticals announces expanded coverage for Crexont